Completed PHASE2 INTERVENTIONAL 4-arm NCT00617526

Naïve HIV POC Monotherapy Trial

A Multicenter Phase 2a, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naïve Subjects

Sponsor: Ardea Biosciences, Inc.

Conditions HIV Infections

Interventions Placebo RDEA806 1000 mg RDEA806 400 mg RDEA806 600 mg RDEA806 800 mg

Updated 7 times since 2017 Last updated: Dec 20, 2013 Started: Jan 31, 2008 Primary completion: Jun 30, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Infections and is currently completed. Ardea Biosciences, Inc. leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ardea Biosciences, Inc.

Data source: Ardea Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamburg, Germany
• London, United Kingdom